BaricitinibHerpes zoster, rebound effect in the form of flare of granuloma annulare and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1977卷 / 1期

关键词：

D O I：

10.1007/s40278-023-47144-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：70 / 70

相关论文

共 50 条

[1] Multiple drugsWorsening of generalised granuloma annulare, lack of efficacy and off-label use: case report
Reactions Weekly, 2023, 1954 (1) : 369 - 369
[2] Dexamethasone/rituximabCOVID-19 recurrence, rebound effect in the form of fever flare-up and off-label use: case report
Reactions Weekly, 2022, 1920 (1) : 191 - 191
[3] Curcumin/secukinumabGranuloma annulare and off-label use: case report
Reactions Weekly, 2021, 1853 (1) : 152 - 152
[4] Prednisone/tocilizumabNeutropenia following off-label use and rebound effect in the form of recurrence of scleritis: case report
Reactions Weekly, 2020, 1817 (1) : 282 - 282
[5] Calcitonin/denosumabVarious toxicities, rebound effect and off-label use: case report
Reactions Weekly, 2021, 1842 (1) : 105 - 105
[6] Ciclosporin/ruxolitinibRenal impairment, off-label use and rebound-effect of ruxolitinib: case report
Reactions Weekly, 2020, 1806 (1) : 87 - 87
[7] Multiple drugsHepatitis B reactivation followed by rebound effect and off-label use: case report
Reactions Weekly, 2024, 2021 (1) : 333 - 333
[8] TofacitinibHerpes zoster reactivation and LOE following off-label use: case report
Reactions Weekly, 2023, 1956 (1) : 482 - 482
[9] Multiple drugsLack of efficacy following off-label use and rebound effect in the form of thrombocytopenia: 2 case reports
Reactions Weekly, 2023, 1950 (1) : 276 - 276
[10] Nirmatrelvir+ritonavirViral load rebound following off-label use: case report
Reactions Weekly, 2022, 1933 (1) : 348 - 348

← 1 2 3 4 5 →